Compare Eli Lilly And Co (LLY) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Snowflake Inc — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Snowflake Inc trades at $369.05 (market cap $121.15B). The key difference: Eli Lilly And Co is far larger — about 8.6× Snowflake Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Snowflake Inc for 54 Days on average.
| LLY | SNOW | |
|---|---|---|
Market Cap | $1.04T | $121.15B |
Volume | 3,064,878 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $1.28K | $356.47 |
52-Week Low | $799.57 | $121.11 |
Typical Hold Time | 93 Days | 54 Days |
Enterprise Value | $1.09T | $121.57B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
SNOW trades at $368.89, up 10.83% in 24 hours, reflecting strong momentum. The technical outlook is bullish, with the stock above key support levels. Fundamentally, revenue growth is robust, reaching $3.63B in 2025, but profitability remains a challenge with a net income margin of -20.07%. Recent news highlights strategic partnerships, such as the UiPath integration, and a $3.75B convertible note offering to fund growth initiatives.
The outlook is supported by analyst optimism, with an 81% buy rating and a $418.03 price target, suggesting 13% upside. However, persistent losses, high valuation multiples, and execution risks in a competitive cloud data market pose significant challenges. Investor sentiment is positive but cautious due to these fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
